Momenta Phama (MNTA) Tops Q3 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. CRWD
5. DOX
6. VRTX
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to Momenta Phama (MNTA) Tops Q3 EPS by 4c

Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results

November 2, 2016 8:00 AM EDT

--Company appoints Scott M. Storer as SVP and CFO--

--Initiates Phase 1 trial for M834, biosimilar ORENCIA® (abatacept) candidate--

CAMBRIDGE, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2016.

For the third quarter of 2016, the Company reported total revenues of $29.1 million, including $23.3 million in product revenues from Sandozs sale of Glatopa® (glatiramer acetate injection). For the nine months ended September 30, 2016, the Company reported total revenues of $75.4 million, including... More